Phreesia Inc

Phreesia Inc(PHR)股票分析

$10.940

-0.100 (-0.91%)收盘时

Loading chart…
最高
11.350
开盘
11.170
成交量加权均价
11.06
成交量
655.03K
市值
1.21B
最低
10.895
成交额
7.25M
企业价值/息税折旧摊销前利润(TTM)
9.92

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

AI 分析 of Phreesia Inc (PHR)

持有

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

估值指标

Phreesia Inc(PHR)当前预期市盈率为 12.02,5 年平均预期市盈率为 3.90。

预期市盈率

合理
5 年均值 P/E
3.90
当前P/E
12.02
高估
193.19
低估
-185.39

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-21.60
当前EV/EBITDA
9.92
高估
98.29
低估
-141.49

预期市销率

低估
5 年均值 P/S
3.62
当前P/S
1.28
高估
5.94
低估
1.30

Alphio AI 对 PHR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%PHR

$23.17

情景价格

基

基准

基准 · 50%PHR

$22.64

情景价格

悲

悲观

悲观 · 25%PHR

$21.67

情景价格

持有 PHR 的大户

P

Pale Fire Capital SE

+ 持有PHR

-2.45%

3个月收益率

事件时间线

2026-09-02 (ET)

19:30:00

Major Indices Bounce Back as ADP Employment Data Falls Short

16:30:00

Phreesia Reports Q2 Revenue of $129.5M, Beating Expectations

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Maintains Fiscal 2027 Revenue Outlook at $510M to $520M

资讯

PHR 常见问题 —— 由 Alphio AI 解答

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易